Clinical Trial Update: A Biomarker-driven, Open Label, Single Arm, Multicentre Phase II Study of Abemaciclib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Who Failed to Platinum-based Therapy [Phase 2]

View source ↗

Summary

Phase II biomarker-driven, open-label, single-arm, multicenter study evaluating abemaciclib in patients with recurrent or metastatic head and neck squamous cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Abemaciclib (abemaciclib)

Snippet

Sponsor: Seoul National University Hospital | Conditions: HNSCC, Head and Neck Neoplasms | Phase 2 | Status: UNKNOWN